RU2019111037A3 - - Google Patents

Download PDF

Info

Publication number
RU2019111037A3
RU2019111037A3 RU2019111037A RU2019111037A RU2019111037A3 RU 2019111037 A3 RU2019111037 A3 RU 2019111037A3 RU 2019111037 A RU2019111037 A RU 2019111037A RU 2019111037 A RU2019111037 A RU 2019111037A RU 2019111037 A3 RU2019111037 A3 RU 2019111037A3
Authority
RU
Russia
Application number
RU2019111037A
Other languages
Russian (ru)
Other versions
RU2019111037A (ru
RU2790288C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019111037A publication Critical patent/RU2019111037A/ru
Publication of RU2019111037A3 publication Critical patent/RU2019111037A3/ru
Application granted granted Critical
Publication of RU2790288C2 publication Critical patent/RU2790288C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019111037A 2016-09-14 2017-06-20 Антитела, связывающие cd3 RU2790288C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662394360P 2016-09-14 2016-09-14
US62/394,360 2016-09-14
US201762491908P 2017-04-28 2017-04-28
US62/491,908 2017-04-28
PCT/US2017/038377 WO2018052503A1 (en) 2016-09-14 2017-06-20 Cd3 binding antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022103374A Division RU2807216C2 (ru) 2016-09-14 2017-06-20 Антитела, связывающие cd3

Publications (3)

Publication Number Publication Date
RU2019111037A RU2019111037A (ru) 2020-10-15
RU2019111037A3 true RU2019111037A3 (cg-RX-API-DMAC7.html) 2020-11-26
RU2790288C2 RU2790288C2 (ru) 2023-02-16

Family

ID=

Also Published As

Publication number Publication date
AU2017327723A1 (en) 2019-05-02
CO2019003706A2 (es) 2019-06-28
HRP20240767T1 (hr) 2024-09-13
CN114395048A (zh) 2022-04-26
CA3036550A1 (en) 2018-03-22
JP2026021330A (ja) 2026-02-10
CR20190198A (es) 2019-10-11
RU2022103374A (ru) 2022-03-02
US11421027B2 (en) 2022-08-23
SA522431672B1 (ar) 2023-11-12
KR20250088655A (ko) 2025-06-17
JP2024023252A (ja) 2024-02-21
EP4050034A1 (en) 2022-08-31
JP2024023251A (ja) 2024-02-21
BR122022002481A2 (cg-RX-API-DMAC7.html) 2019-06-11
JP2023156342A (ja) 2023-10-24
IL290517B1 (en) 2024-08-01
MX2019002967A (es) 2019-07-04
RS65595B1 (sr) 2024-06-28
MX2024011615A (es) 2024-09-30
CN109843325A (zh) 2019-06-04
CL2021003289A1 (es) 2022-07-15
MY200988A (en) 2024-01-27
NZ752294A (en) 2025-09-26
JP7030109B2 (ja) 2022-03-04
CR20220578A (es) 2023-01-17
AU2017327723B2 (en) 2022-11-17
JP2024153676A (ja) 2024-10-29
CR20220408A (es) 2022-10-20
US11505606B2 (en) 2022-11-22
RU2019111037A (ru) 2020-10-15
EP3512549A4 (en) 2020-06-17
CL2022003769A1 (es) 2023-07-21
WO2018052503A1 (en) 2018-03-22
PE20190976A1 (es) 2019-07-09
PT4050034T (pt) 2024-05-27
KR20220032640A (ko) 2022-03-15
KR20240044520A (ko) 2024-04-04
EP4417263A3 (en) 2024-11-20
CL2021003290A1 (es) 2022-07-15
US20250340638A1 (en) 2025-11-06
IL290517A (en) 2022-04-01
US20220025047A1 (en) 2022-01-27
JP7321303B2 (ja) 2023-08-04
ECSP19026304A (es) 2019-06-30
JP2022061993A (ja) 2022-04-19
JP7521728B2 (ja) 2024-07-24
IL290517B2 (en) 2024-12-01
SA523442262B1 (ar) 2024-05-19
UA126384C2 (uk) 2022-09-28
LT4050034T (lt) 2024-06-10
KR102507537B1 (ko) 2023-03-08
FI4050034T3 (fi) 2024-06-10
KR20230035706A (ko) 2023-03-14
SI4050034T1 (sl) 2024-07-31
EP3512549A1 (en) 2019-07-24
JP2022061992A (ja) 2022-04-19
IL265321B2 (en) 2024-01-01
CN109843325B (zh) 2023-10-03
ZA202203250B (en) 2022-05-25
EP4417263A2 (en) 2024-08-21
KR20190052048A (ko) 2019-05-15
JP7521729B2 (ja) 2024-07-24
HUE066651T2 (hu) 2024-08-28
EP4050034B1 (en) 2024-05-08
IL313895A (en) 2024-08-01
DOP2019000059A (es) 2019-06-16
CL2019000643A1 (es) 2019-08-09
US20260085115A1 (en) 2026-03-26
PH12019500545A1 (en) 2019-07-29
DK4050034T3 (da) 2024-06-03
KR102507537B9 (ko) 2025-01-10
PE20241349A1 (es) 2024-07-03
MX2022002018A (es) 2022-03-11
US20230272075A1 (en) 2023-08-31
IL265321A (en) 2019-05-30
US20200048348A1 (en) 2020-02-13
ES2980623T3 (es) 2024-10-02
AU2022201278A1 (en) 2022-03-17
BR122022002481A8 (pt) 2023-02-07
DOP2022000233A (es) 2022-11-30
BR112019004873A2 (pt) 2019-06-11
CN114395048B (zh) 2025-01-28
CN117603353A (zh) 2024-02-27
DOP2023000165A (es) 2023-10-15
KR102505681B1 (ko) 2023-03-06
MX2024011616A (es) 2024-09-30
JP7431868B2 (ja) 2024-02-15
AU2022201278B2 (en) 2022-04-21
PL4050034T3 (pl) 2024-07-22
IL265321B1 (en) 2023-09-01
JP2019536430A (ja) 2019-12-19
US20230082151A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
BR112018068177A2 (cg-RX-API-DMAC7.html)
BR112019002665A2 (cg-RX-API-DMAC7.html)
BR112018004986A2 (cg-RX-API-DMAC7.html)
BR112019001429A2 (cg-RX-API-DMAC7.html)
BR212018070320U2 (cg-RX-API-DMAC7.html)
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112019001236B1 (pt) Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019006736A2 (cg-RX-API-DMAC7.html)
BR112019003108A2 (cg-RX-API-DMAC7.html)
CN303634201S (zh) 轮胎(陆通hf01)
CN303638988S (zh) 包装瓶
CN303626936S (zh) 铝塑盖(a款)
CN303645028S (zh) 糖果瓶(1)
CN303607798S (zh) LED灯(Mini Lighting-067)
CN303613235S (zh) 玩具(男孩Boy_C)
CN303536045S (zh) 嫁衣(15)
CN303537535S (zh) 车家床(四六分圆拉床半围)
CN303536111S (zh) 眼罩(条纹)
CN303536110S (zh) 眼罩(花纹)
CN303536262S (zh) 拖鞋(6)
CN303537405S (zh) 凳子(2076)